We are live on ! Find out more
EDIT icon

Editas Medicine
EDIT

193 hedge funds and large institutions have $90.9M invested in Editas Medicine in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 52 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $1.83M | Put options by funds: $596K

78% more capital invested

Capital invested by funds: $51M → $90.9M (+$39.9M)

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

1% less funds holding

Funds holding: 194 → 193 (-1)

8% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 52

3.69% less ownership

Funds ownership: 53.03% → 49.34% (-3.7%)

Holders
193
Holders Change
-1
Holders Change %
-0.52%
% of All Funds
2.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
48
Reduced
52
Closed
26
Calls
$1.83M
Puts
$596K
Net Calls
+$1.24M
Net Calls Change
+$907K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.6M
2
WP
Woodline Partners
California
+$1.38M
3
N
Nuveen
North Carolina
+$1.04M
4
Citadel Advisors
Citadel Advisors
Florida
+$854K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$587K

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$3.02M
2
Morgan Stanley
Morgan Stanley
New York
-$2.03M
3
UBS Group
UBS Group
Switzerland
-$959K
4
Bank of America
Bank of America
North Carolina
-$717K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$589K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
151
Islay Capital Management
Texas
$660 – – –
NFSG
152
Newbridge Financial Services Group
Florida
$660 – – –
RIL
153
Rothschild Investment LLC
Illinois
$660 +$245 +150 +100%
LFG
154
Larson Financial Group
Missouri
$537 – – –
HPC
155
HM Payson & Co
Maine
$462 – – –
TSMHT
156
Thurston Springer Miller Herd & Titak
Indiana
$451 – – –
RP
157
Raelipskie Partnership
Ontario, Canada
$440 – – –
WIM
158
Westside Investment Management
California
$440 – – –
AAP
159
Arax Advisory Partners
Colorado
$330 – – –
SIS
160
Sound Income Strategies
Florida
$330 – – –
AG
161
AmeriFlex Group
Nevada
$318 – – –
TWD
162
True Wealth Design
Ohio
$284 -$2.39K -1,460 -92%
GWSA
163
Global Wealth Strategies & Associates
Colorado
$275 – – –
CA
164
CoreCap Advisors
Michigan
$253 – – –
PMFA
165
Plante Moran Financial Advisors
Michigan
$220 – – –
VCM
166
Versant Capital Management
Arizona
$220 – – –
NMG
167
New Millennium Group
Utah
$220 +$164 +100 New
Comerica Bank
168
Comerica Bank
Texas
$207 – – –
CW
169
Curio Wealth
Maryland
$169 +$124 +76 +7,600%
KFI
170
Key Financial Inc
Pennsylvania
$165 – – –
MBFW
171
Morton Brown Family Wealth
Pennsylvania
$143 – – –
TC
172
Truvestments Capital
Florida
$134 – – –
PA
173
Parallel Advisors
California
$132 – – –
DIP
174
DT Investment Partners
Pennsylvania
$119 – – –
GWP
175
Gen-Wealth Partners
Michigan
$117 – – –
5 6
7
8 9

EDIT Hedge Fund Activity: Q2 2025 in Review

193 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2025, worth a combined $90.9M — up 78% from $51M a quarter earlier.

Fund positioning in EDIT was balanced in Q2 2025: 26 funds opened new positions, 26 closed out, 48 added to existing stakes and 52 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.6M. The largest seller was UBS AM, exiting entirely with an estimated $3.02M sold.

  • 193 institutional investors held Editas Medicine (EDIT) as of Q2 2025, down from 194 in Q1 2025.
  • Funds reported $90.9M of Editas Medicine stock for Q2 2025, up 78% quarter-over-quarter.
  • 26 funds opened new Editas Medicine positions in Q2 2025 and 26 closed out, a net change of 0 holders.
  • The largest Editas Medicine buyer in Q2 2025 was Millennium Management, an estimated $2.6M added.
  • The largest Editas Medicine seller in Q2 2025 was UBS AM, an estimated $3.02M sold.

Based on aggregated 13F filings for Q2 2025.